David Siwicki

462 total citations
21 papers, 311 citations indexed

About

David Siwicki is a scholar working on Cellular and Molecular Neuroscience, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, David Siwicki has authored 21 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cellular and Molecular Neuroscience, 10 papers in Psychiatry and Mental health and 7 papers in Pharmacology. Recurrent topics in David Siwicki's work include Neurotransmitter Receptor Influence on Behavior (12 papers), Attention Deficit Hyperactivity Disorder (10 papers) and Substance Abuse Treatment and Outcomes (4 papers). David Siwicki is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (12 papers), Attention Deficit Hyperactivity Disorder (10 papers) and Substance Abuse Treatment and Outcomes (4 papers). David Siwicki collaborates with scholars based in United States, Hungary and India. David Siwicki's co-authors include Kenneth Blum, Rajendra D. Badgaiyan, Edward J. Modestino, Mary Hauser, Lisa Lott, Bruce Steinberg, Thomas McLaughlin, David Baron, Brent Boyett and Marjorie C. Gondré‐Lewis and has published in prestigious journals such as Molecular Neurobiology, Current Pharmaceutical Biotechnology and Journal of Behavioral Addictions.

In The Last Decade

David Siwicki

21 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Siwicki United States 13 154 141 119 50 48 21 311
Mary Hauser United States 11 152 1.0× 110 0.8× 86 0.7× 74 1.5× 49 1.0× 20 327
Siobhan Morse United States 9 122 0.8× 91 0.6× 58 0.5× 45 0.9× 57 1.2× 18 308
Kristina Dushaj United States 12 102 0.7× 104 0.7× 73 0.6× 44 0.9× 44 0.9× 23 275
Patrick Rhoades United States 7 130 0.8× 110 0.8× 60 0.5× 37 0.7× 55 1.1× 8 278
Brent Boyett United States 9 89 0.6× 85 0.6× 72 0.6× 27 0.5× 33 0.7× 16 206
Killian A. Welch United Kingdom 9 67 0.4× 104 0.7× 77 0.6× 41 0.8× 99 2.1× 11 318
Deborah A. Deliyannides United States 11 55 0.4× 170 1.2× 180 1.5× 82 1.6× 52 1.1× 18 448
Karolina Kozak Canada 8 74 0.5× 95 0.7× 57 0.5× 107 2.1× 110 2.3× 14 374
Jenessa S. Price United States 10 121 0.8× 108 0.8× 286 2.4× 51 1.0× 120 2.5× 17 451

Countries citing papers authored by David Siwicki

Since Specialization
Citations

This map shows the geographic impact of David Siwicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Siwicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Siwicki more than expected).

Fields of papers citing papers by David Siwicki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Siwicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Siwicki. The network helps show where David Siwicki may publish in the future.

Co-authorship network of co-authors of David Siwicki

This figure shows the co-authorship network connecting the top 25 collaborators of David Siwicki. A scholar is included among the top collaborators of David Siwicki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Siwicki. David Siwicki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boyett, Brent, Rajendra D. Badgaiyan, Panayotis K. Thanos, et al.. (2020). Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. PubMed. 6(1). 1–4. 7 indexed citations
2.
3.
4.
Blum, Kenneth, David Baron, Lisa Lott, et al.. (2019). In Search of Reward Deficiency Syndrome (RDS)-Free Controls: The “Holy Grail” in Genetic Addiction Risk Testing. PubMed. 9(1). 7–21. 20 indexed citations
5.
Blum, Kenneth, Marjorie C. Gondré‐Lewis, Edward J. Modestino, et al.. (2019). Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization. Molecular Neurobiology. 56(11). 7836–7850. 25 indexed citations
6.
Modestino, Edward J., David Siwicki, Lisa Lott, et al.. (2019). Hypodopaminergia and “Precision Behavioral Management” (PBM): It is a Generational Family Affair. Current Pharmaceutical Biotechnology. 21(6). 528–541. 40 indexed citations
7.
Blum, Kenneth, David Baron, Abdalla Bowirrat, et al.. (2019). Death by Opioids: Are there non-addictive scientific solutions?. PubMed. 5(2). 16 indexed citations
8.
9.
10.
Blum, Kenneth, David Siwicki, David Baron, Edward J. Modestino, & Rajendra D. Badgaiyan. (2018). The benefits of genetic addiction risk score (GARS®) and pro-dopamine regulation in combating suicide in the American Indian population. PubMed. 4(2). 9 indexed citations
11.
McLaughlin, Thomas, Kenneth Blum, Bruce Steinberg, et al.. (2018). Pro-dopamine regulator, KB220Z, attenuates hoarding and shopping behavior in a female, diagnosed with SUD and ADHD. Journal of Behavioral Addictions. 7(1). 192–203. 16 indexed citations
12.
Blum, Kenneth, Edward J. Modestino, Marjorie C. Gondré‐Lewis, et al.. (2018). The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD).. PubMed. 2018(1). 23 indexed citations
13.
Blum, Kenneth, Edward J. Modestino, Marjorie C. Gondré‐Lewis, et al.. (2018). The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD). 3(1). 8 indexed citations
14.
Blum, Kenneth, Edward J. Modestino, Rajendra D. Badgaiyan, et al.. (2018). Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.. PubMed. 7(8). 564–579. 17 indexed citations
15.
Blum, Kenneth, Edward J. Modestino, Lisa Lott, et al.. (2018). Introducing "Precision Addiction Management (PAM®)" as an Adjunctive Genetic Guided Therapy for Abusable Drugs in America.. PubMed. 1(2). 1–4. 9 indexed citations
16.
Blum, Kenneth, Lisa Lott, David Siwicki, et al.. (2018). Genetic Addiction Risk Score (GARS™) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis.. PubMed. 1(1). 12 indexed citations
17.
Blum, Kenneth, Edward J. Modestino, Marcelo Febo, et al.. (2017). Lyme and dopaminergic function: Hypothesizing reduced reward deficiency symptomatology by regulating dopamine transmission. PubMed. 3(3). 9 indexed citations
18.
McLaughlin, Thomas, Kenneth Blum, Bruce Steinberg, et al.. (2017). Hypothesizing Las Vegas and Sutherland Springs Mass Shooters Suffer from Reward Deficiency Syndrome: “Born Bad”. PubMed. 3(2). 28–31. 3 indexed citations
19.
Blum, Kenneth, Edward J. Modestino, Bernard W. Downs, et al.. (2017). “Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic. PubMed. 3(6). 15 indexed citations
20.
Blum, Kenneth, Edward J. Modestino, Marjorie C. Gondré‐Lewis, et al.. (2017). GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM™): LESSONS LEARNED FROM AMERICA.. PubMed. 2(1). 17–22. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary Hauser Breakdown of academic impact, for papers by Siobhan Morse Breakdown of academic impact, for papers by Kristina Dushaj Breakdown of academic impact, for papers by Patrick Rhoades Breakdown of academic impact, for papers by Brent Boyett Breakdown of academic impact, for papers by Killian A. Welch Breakdown of academic impact, for papers by Deborah A. Deliyannides Breakdown of academic impact, for papers by Karolina Kozak Breakdown of academic impact, for papers by Jenessa S. Price
Rankless by CCL
2026